The term "Rolex Trial" isn't a formally recognized name within the medical literature. It's highly probable that this refers to a specific clinical trial investigating the use of a zotarolimus-eluting stent (ZES) manufactured by Medtronic, often associated with the brand name "Endeavor." This article will explore the implications of such a trial, drawing upon the provided information and general knowledge of coronary intervention procedures and associated research. We will examine various aspects, including patient demographics, laboratory findings, device specifications, procedural codes, and the role of Medtronic in the development and dissemination of the technology. It's crucial to understand that without the precise name and publication details of the specific trial, this analysis will be based on general knowledge and extrapolation from similar studies.
Rolex Patient Studies (Inferential Analysis)
The statement "The ROLEX registry included patients with significant left main stenosis of low-to-intermediate anatomical complexity (SYNTAX score ≤ 32) treated with the zotarolimus-eluting..." indicates a focus on a specific patient population. Let's break down the key characteristics:
* Significant Left Main Stenosis: This refers to a narrowing of the left main coronary artery, the largest artery supplying blood to the heart. Stenosis, or narrowing, reduces blood flow, leading to angina (chest pain), shortness of breath, and potentially a heart attack. Left main stenosis is particularly serious due to the artery's crucial role.
* Low-to-Intermediate Anatomical Complexity (SYNTAX Score ≤ 32): The SYNTAX score is a widely used system for assessing the complexity of coronary artery disease. It considers factors like the number of diseased vessels, the location and severity of blockages, and the presence of calcification. A score of ≤ 32 indicates a relatively less complex lesion, suggesting that the trial likely excluded patients with extremely challenging anatomy, which might influence the outcome and generalizability of the results. This selection criterion likely aimed to improve the chances of successful intervention and reduce procedural complications.
* Zotarolimus-Eluting Stent (ZES): This is a type of drug-eluting stent (DES). DESs are metallic scaffolds placed within the narrowed artery to restore blood flow. Zotarolimus, a drug incorporated into the stent, slowly releases into the surrounding tissue, preventing the recurrence of stenosis by inhibiting cell proliferation and reducing inflammation. The use of ZES in this trial suggests an investigation into its efficacy and safety in treating left main stenosis.
The overall patient population in a hypothetical "Rolex" trial would likely consist of individuals with symptomatic left main coronary artery disease, deemed suitable for percutaneous coronary intervention (PCI) based on their anatomical characteristics and overall health. Detailed patient characteristics, such as age, gender, risk factors for coronary artery disease (e.g., hypertension, diabetes, smoking), and baseline clinical parameters (e.g., ejection fraction, creatinine levels), would be documented and analyzed to understand the impact of the intervention.
Rolex Lab Results (Inferential Analysis)
Lab results from such a trial would comprehensively assess the efficacy and safety of the ZES. Key areas of investigation would include:
current url：https://fhagqr.d793y.com/global/rolex-trial-25398
burberry mini banner bag review christian dior monsieur polo